There are 12 self-paid medicines in the collection of 18 varieties!

In the context of the normalization and institutionalization of bulk purchases, self-paid medicines can no longer be immu.

"Eight provinces and two districts" with volume procurement

There are 12 self-paid medicines in the collection of 18 varieties

On the evening of July 6, the "Eight Provinces and Two Districts" issued the "Announcement on Carrying out the "Eight Provinces and Two Districts" Fourth Batch of Inter-Provincial Alliance Drug Concentration and Volume Procurement", announcing the launch of the fourth batch of 18 varieties of dru.

It is worth noting that among the 18 varieties, 12 varieties are self-paying drugs!

The following is a detailed list of 12 self-paid medicines in this round of procurement catalogues for eight provinces and two distric.

It is worth mentioning that both diosmin and compound α-ketoacid are clearly required for oral normal-release dosage forms in the bulk purchase of eight provinces and two districts, but the current problem is that these two varieties of tablets The medicine belongs to the national medical insurance, while the capsule belongs to the non-medical insuran.

This is reminiscent of the recent seven batches and eight rounds of national mini.

However, the vitality of this variety is tenacio.

That is to say, in this round of national procurement, Edaravong has already staged a good show of national talk + non-medical insurance competition in the same gro.

12 varieties

Mostly focus on monitoring and adjuvant medication

However, what is even more striking is that among these 12 varieties, at least 8 varieties have been included in the local key monitoring and auxiliary drug catalogue, and some are still within the key monitoring scope of some prefecture-level citi.

Of course, from the perspective of therapeutic areas, tumors, infections, and cardiovascular diseases are still the key areas for centralized collection, but it has to be considered that, as long as they have entered the local monitoring and national-level rational use lists, they will have a high probability of entering the collecti.

The reason why it is said that those with small sales volume will also be purchased with volume, especially non-medical insurance products, is actually a confusing thi.

It is worth mentioning that, of these 12 varieties, 7 varieties have been purchased with quanti.

       From the price point of view, in fact, the price of oral normal-release dosage forms has already broken one yuan per tabl.

       What are the conditions for non-medical insurance drugs to enter the centralized procurement?

       Well, now the question is, in the past, non-medical insurance can still be exempted from the impact of bulk purchases, but with the inclusion of three non-medical insurance varieties, Ambrisentan, Tadalafil, and Albumin Paclitaxel in the second batch and third round, the average drop was more than 6

       The first pilot of the national procurement of non-medical insurance varieties fully shows that the national procurement is to reduce the medical expenses of patients and truly solve the problem of "expensive medical treatment" for ordinary peop.

       Then we will look at the attitude of local procurement with volume to non-medical insurance varieties in recent yea.

       First, the majority of injectio.

       Second, involving chronic diseases and other fiel.

        Manufacturers are concentrated in clusters, and they are recruited but not scatter.

The price reduction will not result in the loss of varieti.

       Fourth, the price has a large room for adjustme.

        Have experience of local or national surveillan.

        No matter how few varieties the sales volume is, it must be at least 200 million or mo.

Basically, about 500 million is the mainstre.

       In this way, relevant companies should have this big account in mi.

The replacement and upgrading of dosage forms + clinical path + rational growth rate should be the adjustment path that relevant companies must choo.

       Procurement of non-medical insurance products with volume is not a simple medical insurance fee control as the industry usually understan.

Fee control is only a mea.

How to adjust medical behavior and standardize rational drug use can not only promote the healthy development of the industry, but also meet clinical nee.

ultimate go.

For non-medical insurance varieties, since the fate of purchasing with quantity cannot be avoided, what we need to do is to improve our own variety structure, strengthen the evidence-based advantages of products, and add and subtract the best, so as to deal with the challeng.